Publications by authors named "M Bakre"
Background: The current study analyzes the pattern of recurrence/relapse in breast cancer patients belonging to different receptor subtypes to help enhance therapeutic and surveillance methods.
Methods: This is an observational prospective study of a cohort of 543 patients from South India. Associations between various factors and their significance in relapse were assessed by odds ratio (OR), Chi-square test, and two-sided P value.
Comparison of Risk Stratification by CanAssist Breast Test Performed on Core Needle Biopsies Versus Surgical Specimens in Hormone Receptor-Positive, Her2-Negative Early Breast Cancer.
Cureus
September 2024
Article Synopsis
- Core needle biopsies (CNB) are increasingly used for biomarker testing in breast cancer, with the CanAssist Breast (CAB) test assessing the risk of recurrence in early-stage hormone receptor-positive, Her2-negative patients.
- A study of 103 paired samples showed a high concordance rate of 92.2% between CNB and surgical specimens, indicating that CAB performed on CNB provides reliable risk stratification.
- The accuracy of CAB in identifying low-risk patients is particularly notable at 97.5%, allowing for informed treatment decisions, such as avoiding unnecessary chemotherapy.
Background: Assessment of Ki67 by immunohistochemistry (IHC) has limited utility in clinical practice owing to analytical validity issues. According to International Ki67 Working Group (IKWG) guidelines, treatment should be guided by a prognostic test in patients expressing intermediate Ki67 range, >5%-<30%. The objective of the study is to compare the prognostic performance of CanAssist Breast (CAB) with that of Ki67 across various Ki67 prognostic groups.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on the long-term recurrence risk in women with hormone receptor-positive, HER2-negative breast cancer, using data from the TEAM trial involving nearly 10,000 patients across multiple countries, including 2,754 from the Netherlands.
- The research specifically evaluates the effectiveness of the CanAssist Breast (CAB) prognostic test in predicting ten-year clinical outcomes for Dutch patients, finding significant associations with risk stratification.
- Results reveal that CAB identified 67.5% of patients as low-risk and 32.5% as high-risk at ten years, with high-risk patients showing worse distant recurrence-free intervals and being independent prognostic factors compared to other clinical parameters.
Aims: Clinicians use multi-gene/biomarker prognostic tests and free online tools to optimize treatment in early ER+/HER2- breast cancer. Here we report the comparison of recurrence risk predictions by CanAssist Breast (CAB), Nottingham Prognostic Index (NPI), and PREDICT along with the differences in the performance of these tests across Indian and European cohorts.
Methods: Current study used a retrospective cohort of 1474 patients from Europe, India, and USA.